Prudential Financial Inc Supernus Pharmaceuticals, Inc. Transaction History

Prudential Financial Inc

$70 Billion
Q3 2024

A detailed history of Prudential Financial Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 58,381 shares of SUPN stock, worth $2.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,381

Previous 59,706 2.22%

Holding current value

$2.11 Million

Previous $1.6 Million 13.96%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$25.77 - $35.16 $34,145 - $46,586	-1,325 Reduced 2.22%	58,381 $1.82 Million
Q2 2024 Aug 13, 2024	SELL	$25.99 - $33.85 $55,202 - $71,897	-2,124 Reduced 3.44%	59,706 $1.6 Million
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $49,177 - $63,798	-1,814 Reduced 2.85%	61,830 $2.11 Million
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $31,921 - $41,700	-1,405 Reduced 2.16%	63,644 $1.84 Million
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $90,567 - $108,109	-3,285 Reduced 4.81%	65,049 $1.79 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $433,844 - $561,778	14,505 Added 26.95%	68,334 $2.05 Million
Q1 2023 May 12, 2023	SELL	$34.93 - $42.03 $54,979 - $66,155	-1,574 Reduced 2.84%	53,829 $1.95 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $2,331 - $2,841	-75 Reduced 0.14%	55,403 $0
Q3 2022 Nov 04, 2022	SELL	$28.79 - $35.41 $114,325 - $140,613	-3,971 Reduced 6.68%	55,478 $1.85 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $22,569 - $30,516	-891 Reduced 1.48%	59,449 $1.7 Million
Q1 2022 May 13, 2022	SELL	$28.51 - $32.9 $726,634 - $838,522	-25,487 Reduced 29.7%	60,340 $1.95 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $2.46 Million - $3.2 Million	-93,420 Reduced 52.12%	85,827 $2.51 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $1.75 Million - $2.33 Million	74,200 Added 70.64%	179,247 $4.89 Million
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $346,077 - $429,876	12,952 Added 14.06%	105,047 $3.24 Million
Q1 2021 May 12, 2021	SELL	$24.15 - $31.45 $10.2 Million - $13.3 Million	-422,358 Reduced 82.1%	92,095 $2.41 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $2.44 Million - $3.56 Million	-137,769 Reduced 21.12%	514,453 $12.9 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $694,193 - $860,868	34,366 Added 5.56%	652,222 $13.6 Million
Q2 2020 Aug 12, 2020	BUY	$17.09 - $24.89 $3.94 Million - $5.74 Million	230,596 Added 59.55%	617,856 $14.7 Million
Q1 2020 May 12, 2020	SELL	$14.45 - $24.69 $2.1 Million - $3.59 Million	-145,571 Reduced 27.32%	387,260 $6.97 Million
Q4 2019 Feb 11, 2020	BUY	$19.93 - $29.13 $4.33 Million - $6.33 Million	217,408 Added 68.93%	532,831 $12.6 Million
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $5.78 Million - $7.57 Million	226,744 Added 255.69%	315,423 $8.67 Million
Q2 2019 Aug 08, 2019	SELL	$29.96 - $38.87 $1.1 Million - $1.43 Million	-36,773 Reduced 29.31%	88,679 $0
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $49,220 - $63,068	1,502 Added 1.21%	125,452 $0
Q4 2018 Feb 07, 2019	SELL	$30.84 - $49.51 $63,222 - $101,495	-2,050 Reduced 1.63%	123,950 $4.12 Million
Q3 2018 Nov 07, 2018	SELL	$42.7 - $56.55 $12.9 Million - $17.1 Million	-302,458 Reduced 70.59%	126,000 $0
Q2 2018 Aug 13, 2018	BUY	$44.1 - $59.85 $1.23 Million - $1.67 Million	27,880 Added 6.96%	428,458 $0
Q1 2018 May 04, 2018	BUY	$37.15 - $46.9 $142,395 - $179,767	3,833 Added 0.97%	400,578 $0
Q4 2017 Feb 13, 2018	SELL	$36.4 - $42.6 $299,390 - $350,385	-8,225 Reduced 2.03%	396,745 $15.8 Million
Q3 2017 Nov 02, 2017	BUY	$36.75 - $49.65 $14.9 Million - $20.1 Million	404,970	404,970 $16.2 Million

Others Institutions Holding SUPN

# of Institutions

279

Shares Held

61M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.

Account

Prudential Financial Inc Supernus Pharmaceuticals, Inc. Transaction History